Alan Ashworth

67.0k citations

269 papers · 37.6k indexed · 15 hit papers · h-index 91

Impact in

Oncology top 0.02%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Cancer Research top 0.05%
- Cancer Genomics and Diagnostics

Papers in

Oncology 131
- PARP inhibition in cancer therapy 65
- Cancer-related Molecular Pathways 19
Molecular Biology 193
- DNA Repair Mechanisms 73
- CRISPR and Genetic Engineering 51
- Genomics and Chromatin Dynamics 19

Co-authors: Christopher J. Lord Andrew Tutt Nuala McCabe Graeme C.M. Smith Manuela Santarosa Jorge S. Reis‐Filho Niall M.B. Martin Johann S. de Bono
Journals: Cancer Research (20 papers)The Journal of Pathology (11 papers)Nucleic Acids Research (8 papers)Oncogene (8 papers)Nature (8 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Alan Ashworth

268 papers receiving 37.0k citations

Hit Papers

15 papers align trajectories log scale

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence 2022 · 201 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Cancer Cell
2018 Cell
2018 Nature Reviews Clinical Oncology
2017 Science
2016 Nature reviews. Cancer
2012 Nature
2010 Journal of Clinical Oncology
2009 New England Journal of Medicine
2008 Nature
2008 Journal of Clinical Oncology
2006 Cancer Research
2005 Nature
1995 Science
1992 Cell
1991 Nature

Peers

Countries citing papers authored by Alan Ashworth

Since Specialization

Citations

This map shows the geographic impact of Alan Ashworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Ashworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Ashworth more than expected).

Fields of papers citing papers by Alan Ashworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Ashworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Ashworth. The network helps show where Alan Ashworth may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alan Ashworth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan Ashworth Line = papers co-authored together Alan Ashworth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors Molecular Cancer Therapeutics ·Anish Thomas, Shaun D. Fontaine, Morgan E. Diolaiti, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi, Linda Sciuto, Samantha Nichols, Alan Ashworth, Felix Y. Feng, Gary W. Ashley, Minh Nguyen, Yves Pommier, Daniel V. Santi	2022	7
2	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models Cancer Research ·Shaun D. Fontaine, Gary W. Ashley, Peter J. Houghton, Raushan T. Kurmasheva, Morgan E. Diolaiti, Alan Ashworth, Cody J. Peer, Sunita S Malaj, William D. Figg, Denis Beckford-Vera, Daniel V. Santi	2020	16
3	Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy Cancer Discovery ·Jonathan Chou, David A. Quigley, Troy M. Robinson, Felix Y. Feng, Alan Ashworth	2020	214
4	PARP inhibitors: Synthetic lethality in the clinic Science ·Christopher J. Lord, Alan Ashworth Hit paper breakdown →	2017	1876
5	Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers Molecular Cancer Therapeutics ·Amy Dréan, Chris T. Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac García-Murillas, Helen N. Pemberton, Jessica Frankum, Rumana Rafiq, Nicholas Badham, James Campbell, Aditi Gulati, Nicholas C. Turner, Stephen J. Pettitt, Alan Ashworth, Christopher J. Lord	2017	58
6	ATR Is a Therapeutic Target in Synovial Sarcoma Cancer Research ·Samuel E. Jones, Emmy D.G. Fleuren, Jessica Frankum, Asha Konde, Chris T. Williamson, Dragomir B. Krastev, Helen N. Pemberton, James Campbell, Aditi Gulati, Richard Elliott, Malini Menon, Joanna Selfe, Rachel Brough, Stephen J. Pettitt, Wojciech Niedźwiedź, Winette T.A. van der Graaf, Janet Shipley, Alan Ashworth, Christopher J. Lord	2017	47
7	Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer Cancer Research ·Shugo Kasuya, Mark N. Brook, Olivia Fletcher, Penny Coulson, Katarzyna Tomczyk, Michael E. Jones, Alan Ashworth, Anthony J. Swerdlow, Nick Orr, Montserrat García‐Closas	2015	43
8	Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways Molecular Cancer Therapeutics ·Marieke Aarts, Ilirjana Bajrami, María Teresa Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, Nicholas C. Turner	2015	48
9	An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor Cancer Discovery ·Nirupa Murugaesu, Marjan Iravani, Antoinette van Weverwijk, Aleksandar Ívetic, Damian A. Johnson, Aristotelis Antonopoulos, Antony Fearns, Mariam Jamal‐Hanjani, David Sims, Kerry Fenwick, Costas Mitsopoulos, Qiong Gao, Nick Orr, Marketa Zvelebil, Stuart M. Haslam, Anne Dell, Helen Yarwood, Christopher J. Lord, Alan Ashworth, Clare M. Isacke	2014	75
10	Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study Cancer Epidemiology Biomarkers & Prevention ·James M. Flanagan, Mark N. Brook, Nick Orr, Katarzyna Tomczyk, Penny Coulson, Olivia Fletcher, Michael E. Jones, Minouk J. Schoemaker, Alan Ashworth, Anthony J. Swerdlow, Robert Brown, Montserrat García‐Closas	2014	47
11	Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors Annual Review of Medicine ·Christopher J. Lord, Andrew Tutt, Alan Ashworth	2014	344
12	Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity Cancer Research ·Ilirjana Bajrami, Jessica Frankum, Asha Konde, Rowan Miller, Farah Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper, Lina Chen, Iwanka Kozarewa, Ioannis Assiotis, Kerry Fenwick, Rachael Natrajan, Christopher J. Lord, Alan Ashworth	2013	279
13	Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase Molecular Cancer Therapeutics ·壹岐伸弥, Mohamed A.M. El Gendy, Ana M. Mendes‐Pereira, Christopher J. Lord, Sunita Ghosh, Edan Foley, Alan Ashworth, Michael Weinfeld	2013	23
14	Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3 -Mutant Cancer Cancer Discovery ·María Teresa Herrera-Abreu, Alex Pearson, James Campbell, Steven D. Shnyder, Margaret A. Knowles, Alan Ashworth, Nicholas C. Turner	2013	98
15	Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk Cancer Research ·Kevin Brennan, Montserrat García‐Closas, Nick Orr, Olivia Fletcher, Michael E. Jones, Alan Ashworth, Anthony J. Swerdlow, Heather Thorne, Elio Ríboli, Paolo Vineis, Miren Dorronsoro, Françoise Clavel‐Chapelon, Salvatore Panico, N. Charlotte Onland‐Moret, Dimitrios Trichopoulos, Rudolf Kaaks, Kay‐Tee Khaw, Robert Brown, James M. Flanagan	2012	118
16	Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1 Cancer Discovery ·Marieke Aarts, Rachel Sharpe, Isaac García-Murillas, Heidrun Gevensleben, Melissa S. Hurd, Stuart D. Shumway, Carlo Toniatti, Alan Ashworth, Nicholas C. Turner	2012	252
17	Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers Cancer Research ·Sarah A. Martin, Madeleine Hewish, David Sims, Christopher J. Lord, Alan Ashworth	2011	69
18	High-Throughput RNAi Screening Reveals Novel Regulators of Telomerase Cancer Research ·Maria Antonietta Cerone, Darren J. Burgess, Cristina Naceur‐Lombardelli, Christopher J. Lord, Alan Ashworth	2011	42
19	A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Clinical Cancer Research ·Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nick Orr, Marina Parton, Ian E. Smith, Jorge S. Reis‐Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner	2010	222
20	Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Cancer Research ·Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth Hit paper breakdown →	2006	977

About Alan Ashworth

Alan Ashworth is a scholar working on Oncology, Molecular Biology, Genetics, Cancer Research and Genetics, having authored 269 papers that have together received 37.6k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (73 papers), PARP inhibition in cancer therapy (65 papers), CRISPR and Genetic Engineering (51 papers), BRCA gene mutations in cancer (31 papers), Cancer Genomics and Diagnostics (30 papers), Cancer-related Molecular Pathways (19 papers), Genomics and Chromatin Dynamics (19 papers) and Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (18 papers). The work is most often cited by research in Oncology (19.4k citations), Cancer Research (6.8k citations), Molecular Biology (26.6k citations), Reproductive Medicine (2.8k citations) and Genetics (7.4k citations). Alan Ashworth has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Christopher J. Lord, Andrew Tutt, Nuala McCabe, Graeme C.M. Smith, Manuela Santarosa, Jorge S. Reis‐Filho, Niall M.B. Martin, Johann S. de Bono, Stephen P. Jackson and Hannah Farmer. Their work appears in journals such as Cancer Research, The Journal of Pathology, Nucleic Acids Research, Oncogene and Nature.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact